What are the primary pharmacologic classes in ophthalmology and representative drugs, including typical concentrations, routes, dosing schedules, and common indications?

Pharmacological Ophthalmology: Primary Drug Classes and Representative Agents

Ophthalmic pharmacology encompasses multiple therapeutic classes targeting specific ocular conditions, with topical administration being the predominant route for anterior segment disease, while posterior segment pathology increasingly requires intravitreal injection.

Anti-Inflammatory Agents

Corticosteroids

• Topical corticosteroids are critical for managing severe adenoviral keratoconjunctivitis with marked chemosis, eyelid swelling, epithelial sloughing, or membranous conjunctivitis 1
• Fluorometholone and loteprednol are preferred for prolonged use as they demonstrate poor ocular penetration and lower risk of IOP elevation or cataract formation 1
• Dosing strategy: Start at higher frequency, then taper to minimum effective dose once inflammation is controlled
• Critical monitoring: Periodic IOP measurement and pupillary dilation assessment for glaucoma and cataract development 1

Common pitfall: Topical corticosteroids potentiate HSV epithelial infections and must be avoided in herpetic disease 1

Immunomodulators

• Cyclosporine 0.05% (twice daily): Inhibits T-cell activation and inflammatory cytokine production; demonstrated 10-mm increase in Schirmer test results at 6 months in 15% of patients versus 5% with vehicle 2

  • Can be reduced to once daily after 1 year of twice-daily therapy without loss of efficacy
  • Ocular burning reported in 17% of patients
  • May function as disease-modifying agent for dry eye syndrome 2
  • Higher compounded concentrations (up to 1%) used for subepithelial infiltrates 1

• Lifitegrast 5% (twice daily): FDA-approved in 2016 for dry eye signs and symptoms; blocks LFA-1/ICAM-1 interaction to prevent T-cell activation and migration 2

Antiviral Agents

Topical Antivirals

• Ganciclovir 0.15% gel: 3-5 times daily for HSV conjunctivitis; less toxic to ocular surface than trifluridine 1
• Trifluridine 1% solution: 5-8 times daily for HSV conjunctivitis; inevitably causes epithelial toxicity if used >2 weeks 1

Oral Antivirals for HSV

• Acyclovir: 200-400 mg five times daily
• Valacyclovir: 500 mg 2-3 times daily
• Famciclovir: 250 mg twice daily
• Note: Oral antivirals alone may be inadequate for HSV blepharoconjunctivitis; addition of topical antiviral treatment is more effective 1

Glaucoma Medications

Beta-Blockers

• Timolol gel-forming solution and levobunolol: Once-daily dosing; remain mainstay first-line agents despite cardiopulmonary adverse effect concerns 3

Prostaglandin Analogues

• Latanoprost and other PGAs: Increasingly important first-line therapy; effective IOP reduction with minimal systemic adverse effects [@6,7@]
• Can be combined additively with beta-blockers, adrenergic agents, topical CAIs, and miotics 3

Alpha-2 Adrenergic Agonists

• Brimonidine: Effective adjunctive agent; may become first-line as systemic adverse effects rarely reported 3

Carbonic Anhydrase Inhibitors

• Topical CAIs: Effective adjunctive therapy for additional IOP reduction 4
• Oral CAIs: Reserved for temporary use (post-surgery/laser) or glaucoma resistant to other treatments 3

Miotics

• Pilocarpine and carbachol: Now recommended as second or third-line drugs due to availability of better-tolerated agents 3
• Cholinesterase inhibitors: Third-line drugs 3

Artificial Tears and Lubricants

• Preserved formulations: Sufficient for mild dry eye with healthy ocular surface
• Preservative-free formulations: Recommended when used >4 times daily or chronically 2
• Evidence: Systematic review found artificial tears safe and effective, though most formulations have comparable efficacy 2

Route-Specific Considerations

Topical Administration

• Primary route for anterior segment disease; requires accurate patient instillation technique 5
• Anatomical and physiological barriers make topical delivery challenging—more so than transdermal, nasal, or gut absorption 5

Intravitreal Injection

• Standard of care for posterior segment disease (vitreous, retina, choroid, optic nerve) using biologics for macular degeneration 5
• Necessary due to additional barriers preventing topical drug penetration to posterior segment 5

Systemic Absorption Risk

Critical caveat: Locally applied ocular medications can be absorbed systemically, causing morbidity and mortality including systemic hypotension, bronchospasm, and bradycardia 5

Pharmaceutical Requirements

Ophthalmic formulations must optimize:

• Solubility at physiological pH
• Osmolarity compatibility
• Sterility and stability
• Minimal CYP450 metabolism (eye has esterases, hydroxylases, transporters but relatively little CYP450) 5